Skip to main content
Erschienen in: World Journal of Urology 4/2014

01.08.2014 | Topic Paper

A comparative assessment of active surveillance for localized prostate cancer in the community versus tertiary care referral center

verfasst von: Andreas Becker, Daniel Seiler, Maciej Kwiatkowski, Luis Alex Kluth, Dietrich Schnell, Markus Graefen, Thorsten Schlomm, Margit Fisch, Franz Recker, Lothar Weissbach, Felix K. H. Chun

Erschienen in: World Journal of Urology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To date, evidence on active surveillance (AS) is restricted to protocol-based studies. Conversely, practice patterns outside of such protocols are unknown. The aim of this study was to capture the current AS treatment patterns for localized prostate cancer in patients managed by office-based urologists compared to patients treated at a tertiary care center.

Methods and materials

Two prospective cohorts were investigated: 361 AS arm patients of the German Hormonal treatment, Active surveillance, Radiation therapy, OP, Watchful waiting (HAROW) study, an observational health service study and 387 protocol-based AS patients treated at the Department of Urology of the Kantonsspital Aarau, Switzerland were included. Observational non-protocol HAROW versus on-protocol Kantonsspital Aarau (KSA) was compared, and active-treatment-free survival represented the primary outcome.

Results

Study population of the observational HAROW versus tertiary care protocol-based KSA cohorts differed statistically significantly regarding age (p < 0.001) and proportion of patients meeting the Chism criteria (p < 0.001). In stratified analyses, AFTS at 1 and 2 years was, respectively, 87.7 % (95 % CI 84.0–91.7) and 75.0 % (95 % CI 69.7–80.8) in HAROW patients compared to 90.8 % (95 % CI 87.8–93.9) and 75.3 % (95 % CI 70.7–80.1) for patients in the KSA cohort (p = 0.97).

Conclusion

We demonstrate significant differences in terms of AS inclusion, surveillance and discontinuation criteria between patients managed by office-based urologists compared to their tertiary care counterparts. Interestingly, the risk of deferred active therapy was equally moderate for both groups in the short-term follow-up.
Literatur
1.
Zurück zum Zitat Measurement of progress against cancer (1990) Extramural committee to assess measures of progress against cancer. J Natl Cancer Inst 82(10):825–835CrossRef Measurement of progress against cancer (1990) Extramural committee to assess measures of progress against cancer. J Natl Cancer Inst 82(10):825–835CrossRef
2.
Zurück zum Zitat Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30PubMedCrossRef Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30PubMedCrossRef
3.
4.
Zurück zum Zitat Bill-Axelson A, Holmberg L, Ruutu M et al (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364(18):1708–1717PubMedCrossRef Bill-Axelson A, Holmberg L, Ruutu M et al (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364(18):1708–1717PubMedCrossRef
5.
Zurück zum Zitat Cooperberg MR, Carroll PR, Klotz L (2011) Active surveillance for prostate cancer: progress and promise. J Clin Oncol 29(27):3669–3676PubMedCrossRef Cooperberg MR, Carroll PR, Klotz L (2011) Active surveillance for prostate cancer: progress and promise. J Clin Oncol 29(27):3669–3676PubMedCrossRef
6.
Zurück zum Zitat Tosoian JJ, Trock BJ, Landis P et al (2011) Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 29(16):2185–2190PubMedCrossRef Tosoian JJ, Trock BJ, Landis P et al (2011) Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 29(16):2185–2190PubMedCrossRef
7.
Zurück zum Zitat van den Bergh RC, Roemeling S, Roobol MJ et al (2009) Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 55(1):1–8PubMedCrossRef van den Bergh RC, Roemeling S, Roobol MJ et al (2009) Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 55(1):1–8PubMedCrossRef
8.
Zurück zum Zitat Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28(1):126–131PubMedCrossRef Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28(1):126–131PubMedCrossRef
9.
Zurück zum Zitat Graefen M, Schlomm T (2013) Active surveillance for low-risk prostate cancer: some questions are answered, but many questions remain. Eur Urol 63(4):604–605PubMedCrossRef Graefen M, Schlomm T (2013) Active surveillance for low-risk prostate cancer: some questions are answered, but many questions remain. Eur Urol 63(4):604–605PubMedCrossRef
10.
Zurück zum Zitat Bul M, Zhu X, Valdagni R et al (2013) Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 63(4):597–603PubMedCrossRef Bul M, Zhu X, Valdagni R et al (2013) Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 63(4):597–603PubMedCrossRef
11.
Zurück zum Zitat Steginga SK, Turner E, Donovan J (2008) The decision-related psychosocial concerns of men with localised prostate cancer: targets for intervention and research. World J Urol 26(5):469–474PubMedCrossRef Steginga SK, Turner E, Donovan J (2008) The decision-related psychosocial concerns of men with localised prostate cancer: targets for intervention and research. World J Urol 26(5):469–474PubMedCrossRef
12.
Zurück zum Zitat Cooperberg MR, Broering JM, Kantoff PW, Carroll PR (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178(3 Pt 2):S14–S19PubMedCentralPubMedCrossRef Cooperberg MR, Broering JM, Kantoff PW, Carroll PR (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178(3 Pt 2):S14–S19PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat van den Bergh RC, Vasarainen H, van der Poel HG et al (2010) Short-term outcomes of the prospective multicentre ‘prostate cancer research international: active surveillance’ study. BJU Int 105(7):956–962PubMedCrossRef van den Bergh RC, Vasarainen H, van der Poel HG et al (2010) Short-term outcomes of the prospective multicentre ‘prostate cancer research international: active surveillance’ study. BJU Int 105(7):956–962PubMedCrossRef
14.
Zurück zum Zitat Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320–1328PubMedCrossRef Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320–1328PubMedCrossRef
15.
Zurück zum Zitat Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A (2004) A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 59(2):380–385PubMedCrossRef Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A (2004) A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 59(2):380–385PubMedCrossRef
16.
Zurück zum Zitat Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271(5):368–374PubMedCrossRef Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271(5):368–374PubMedCrossRef
17.
Zurück zum Zitat Bul M, van den Bergh RC, Zhu X et al (2012) Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int 110(11):1672–1677PubMedCrossRef Bul M, van den Bergh RC, Zhu X et al (2012) Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int 110(11):1672–1677PubMedCrossRef
18.
Zurück zum Zitat Whitson JM, Porten SP, Hilton JF et al (2011) The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol 185(5):1656–1660PubMedCrossRef Whitson JM, Porten SP, Hilton JF et al (2011) The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol 185(5):1656–1660PubMedCrossRef
19.
20.
Zurück zum Zitat Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP (1993) Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71(3 Suppl):933–938PubMedCrossRef Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP (1993) Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71(3 Suppl):933–938PubMedCrossRef
21.
Zurück zum Zitat Bul M, Zhu X, Rannikko A et al (2012) Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol 62(2):195–200PubMedCrossRef Bul M, Zhu X, Rannikko A et al (2012) Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol 62(2):195–200PubMedCrossRef
22.
Zurück zum Zitat Pierorazio PM, Spencer BA, McCann TR, McKiernan JM, Benson MC (2007) Preoperative risk stratification predicts likelihood of concurrent PSA-free survival, continence, and potency (the trifecta analysis) after radical retropubic prostatectomy. Urology 70(4):717–722PubMedCrossRef Pierorazio PM, Spencer BA, McCann TR, McKiernan JM, Benson MC (2007) Preoperative risk stratification predicts likelihood of concurrent PSA-free survival, continence, and potency (the trifecta analysis) after radical retropubic prostatectomy. Urology 70(4):717–722PubMedCrossRef
23.
Zurück zum Zitat Gillitzer R, Hampel C, Thomas C et al (2009) Therapy choices of German urologists and radio-oncologists if personally diagnosed with localized prostate cancer. Urologe A 48(4):399–407PubMedCrossRef Gillitzer R, Hampel C, Thomas C et al (2009) Therapy choices of German urologists and radio-oncologists if personally diagnosed with localized prostate cancer. Urologe A 48(4):399–407PubMedCrossRef
Metadaten
Titel
A comparative assessment of active surveillance for localized prostate cancer in the community versus tertiary care referral center
verfasst von
Andreas Becker
Daniel Seiler
Maciej Kwiatkowski
Luis Alex Kluth
Dietrich Schnell
Markus Graefen
Thorsten Schlomm
Margit Fisch
Franz Recker
Lothar Weissbach
Felix K. H. Chun
Publikationsdatum
01.08.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 4/2014
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-014-1309-2

Weitere Artikel der Ausgabe 4/2014

World Journal of Urology 4/2014 Zur Ausgabe

Männern mit Zystitis Schmalband-Antibiotika verordnen

03.05.2024 Zystitis Nachrichten

Die akute Zystitis von Männern und ihre Therapie sind wenig erforscht. Norwegische Forscher haben das nachgeholt. Ihr Rat: Erst einmal keine Breitbandantibiotika verordnen.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

D-Mannose ohne Nutzen in der Prävention von HWI-Rezidiven

D-Mannose, eine Hoffnungsträgerin in der Rezidivprophylaxe von Harnwegsinfektionen, hat in einer Studie nicht mehr bewirken können als ein Placebo. Die Empfehlung zur Einnahme entfalle damit, so die Autoren.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.